Abstract:PURPOSE: Discovery and development of a novel anticancer PEG-SMR-Clu peptide to prevent breast cancer metastasis. How breast cancer cells and primary mammary epithelial cells interact and communicate with each other to promote tumorigenesis and how to prevent tumor metastasis has long been a concern of researchers. Cancer cells secrete exosomes containing proteins and RNA. These factors can influence tumor development by directly targeting cancer cells and tumor stroma. In this study, we determined the effects of a peptide as an inhibitor of exosome secretion on breast tumors. We developed a peptide derived from the Secretion Modification Region (SMR) of HIV-1 Nef protein that was modified with PEG on the N-terminus and with a Clusterin (Clu)-binding peptide on the C-terminus. Attachment of PEG to the SMR peptide, termed PEGylation, offers improved water solubility and stability as well as reduced clearance through the kidneys, leading to a longer circulation time. The 12-mer Clu-binding peptide plays multiple roles in tumor development and metastasis. The Clu peptide can be detected by antibody in vivo, thus it has the potential to be used to monitor tumor status and treatment efficacy in animal studies and eventually in cancer patients.RESULTS: PEG-SMRwt-Clu and PEG-SMRwt peptides inhibited the growth of both of MCF-7 (estrogen responsive, ER+) and MDA-MD-231 (estrogen non-responsive, ER-) human breast cancer cells in a dose and time-dependent manner, without inducing cytotoxic effects. The SMRwt peptide, combined with paclitaxel, induced G2/M phase cell cycle arrest on MCF-7 and MDA-MB-231 cells but did not promote apoptosis. PEG-SMRwt-Clu peptide treatment blocked exosome release from both MCF-7 and MDA-MB-231 cells. This effect was blocked by knockdown of the chaperone protein mortalin by either antibody or siRNA.MATERIALS AND METHODS: MCF-7 and MDA-MB-231 breast tumor cells were treated with PEG-SMR-Clu peptide alone and in combination with paclitaxel and cisplatin. Cell proliferation and viabilty were determined via cell cycle analysis using Cellometer imaging cytometry, Annexin V and MTT assays. The effects of the PEG-SMR-Clu peptide on tumor exosome release were determined by testing isolated exosome fractions, for (i) expression of CD63 and Alix proteins by Western blotting, (ii) NanoSight nanoparticle tracking analysis (NTA 10) to measure exosomes size and concentration, and (iii) measurement of acetylcholinesterase (AchE) for exosome specific enzyme activity.CONCLUSIONS: PEG-SMRwt-CLU peptides inhibited the growth of human breast cancer cells and blocked tumor exosome release in vitro. The peptide alone did not cause increased cytotoxicity or apoptosis induction, but did cause cell cycle G2/M phase arrest in both estrogen responsive and non-responsive breast cancer cells. These data suggest a potential therapeutic value of SMR to prevent breast cancer metastasis and as an adjuvant for the chemotherapeutic treatment of human breast cancer.

Effect of the Pegylation of Trimeric Β Peptide on It's Anti-metastasis Activity

Effect of laminin tyrosine-isoleucine-glycine-serine-arginine peptide on the growth of human prostate cancer (PC-3) cells in vitro.

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

Inhibitory Effects of Synthetic Β Peptide on Invasion and Metastasis of Liver Cancer

[Molecular Cloning and Expression of Anti-Tumor Adhesion Peptide (Beta3)].

Studies of poly(ethylene glycol) modification of HM-3 polypeptides.

Effect of GSK-3β on Proliferation and Invasion of Endometrioid Adenocarcinoma

Synthesis and Systematic Study on the Effect of Different PEG Units on Stability of PEGylated, Integrin-αvβ6-Specific A20FMDV2 Analogues in Rat Serum and Human Plasma

Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells

Inhibitory effects of anti-adhesion peptides on invasion/metastasis ability of hepatocellular carcinoma cells

Pegylation Potentiates The Effectiveness Of An Antagonistic Peptide That Targets The Ephb4 Receptor With Nanomolar Affinity

Effects of Platelets on Adhesive Ability of Human Hepatoma Cell Lines with Various Metastatic Potential to Extracellular Matrix Protein

Anti-metastatic effects of 1,2,3,4,6-Penta-O-galloyl-β-D-glucose in colorectal cancer: Regulation of cathepsin B-mediated extracellular matrix dynamics and epithelial-to-mesenchymal transition

[Effects of High Metastatic Potential Hepatocellular Carcinoma Cell-Binding Peptide on the Invasion and Metastasis of Liver Cancer].

Pegylated Recombinant Human Tumor Necrosis Factor Alpha: Pharmacokinetics and Anti-Tumor Effects

Linkage with Cathepsin B-sensitive Dipeptide Promotes the in Vitro and in Vivo Anticancer Activity of PEGylated Tumor Necrosis Factor-Alpha (Tnf-Α) Against Murine Fibrosarcoma.

The Effect of Molecular Structure on Cytotoxicity and Antitumor Activity of PEGylated Nanomedicines.

A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy

Experiment Study on the Role of RGD-Modified Endostatin Peptide 30 Derived from Endostatin in the Invasion and Migration Process of SGC-7901 Cells

PEP06 Polypeptide 30 Exerts Antitumour Effect in Colorectal Carcinoma Via Inhibiting Epithelial-Mesenchymal Transition

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity